Chinese Journal of Tissue Engineering Research ›› 2023, Vol. 27 ›› Issue (7): 1017-1022.doi: 10.12307/2023.080

Previous Articles     Next Articles

Sustained releasing of pyrazinamide, capreomycin, moxifloxacin and amikacin loaded bone cement in vitro

Yuan Hucheng1, Ding Yongguo1, Ma Xuehua2, Ma Wenxin3, Sun Jianmin1, Wang Zili4, 5, Jin Weidong3, 5   

  1. 1Pain Department of Ningxia Integrated Traditional Chinese and Western Medicine Hospital, Yinchuan 750021; 2Daxin Community Health Service Center of Yinchuan Third People’s Hospital, Yinchuan 750004; 3General Hospital of Ningxia Medical University, Yinchuan 750004; 4Xi’an International Medical Center Hospital, Xi’an 710000, Shaanxi Province, China; 5Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
  • Received:2021-12-06 Accepted:2022-02-22 Online:2023-03-08 Published:2022-07-18
  • Contact: Jin Weidong, Chief physician, Master’s supervisor, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China; Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China Wang Zili, Chief physician, Doctoral supervisor, Xi’an International Medical Center Hospital, Xi’an 710000, Shaanxi Province, China; Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
  • About author:Yuan Hucheng, Master, Attending physician, Pain Department of Ningxia Integrated Traditional Chinese and Western Medicine Hospital, Yinchuan 750021, Ningxia Hui Autonomous Region, China
  • Supported by:
    Scientific Research Project of Ningxia Medical University, No. XY201828, XY201722 (to JWD, WZL); the National Science Foundation of Ningxia Hui Autonomous Region, No. NZ17145 (to MWX)

PDF

68

Abstract: BACKGROUND: Oral anti-tuberculosis drugs have serious systemic side effects after removal of bone and joint tuberculosis lesions. It is imperative to seek a sustained-release drug system that can not only save drug dosage, but also increase local drug concentration in lesions and reduce systemic blood drug concentration. 
OBJECTIVE: To observe the sustained-release properties of polymethyl methacrylate bone cement loaded with antituberculosis drugs pyrazinamide, capreomycin, moxifloxacin, and amikacin in PBS artificial simulated body fluid. 
METHODS: Polymethyl methacrylate bone cement Palacos R powder was mixed with antituberculosis drugs pyrazinamide, capreomycin, moxifloxacin, and amikacin in the proportion of 40 g:1.5 g and 40 g:2.5 g, respectively. The 20 mL of liquid monomer were added to prepare 8 groups of anti-tuberculosis drug-loaded bone cement standard specimens, with 5 samples in each group. In the control group, 40 g bone cement powder and 20 mL liquid monomer were mixed in the same way to prepare 5 standard bone cement samples without drugs. The drug was soaked in PBS and placed in 37 ℃ constant temperature water bath oscillator. The extract was taken at set time points. The drug concentration of each group was determined by high performance liquid chromatography. 
RESULTS AND CONCLUSION: (1) The time of the lowest drug release concentration in PBS artificial simulated body fluid of pyrazinamide 1.5 g group, pyrazinamide 2.5 g group, capreomycin 1.5 g group, capreomycin 2.5 g group, moxifloxacin 1.5 g group, moxifloxacin 2.5 g group, amikacin 1.5 g group and amikacin 2.5 g group was 45, 60, 150, 150, 120, 120, 60 and 90 days, respectively. Among these groups, the capreomycin 1.5 g group, capreomycin 2.5 g group, moxifloxacin 1.5 g group, moxifloxacin 2.5 g group, and amikacin 2.5 g group had a longer drug release period, while the control group had no drug release. (2) It is concluded that polymethyl methacrylate bone cement loaded with capreomycin (1.5 g and 2.5 g), moxifloxacin (1.5 g and 2.5 g), and amikacin (2.5 g) has a long release cycle and good release performance.

Key words: polymethylmethacrylate, bone cement, antituberculosis drug, sustained release property, tuberculosis of bone and joint, focal debridement, high performance liquid chromatography, sustained-release material

CLC Number: